RM-191A is under clinical development by RR MedSciences and currently in Phase II for Neuropathic Pain (Neuralgia). According to GlobalData, Phase II drugs for Neuropathic Pain (Neuralgia) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RM-191A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RM-191A overview

RM-191A is under development for the treatment of neuropathic pain, inflammation, wound healing. The therapeutic candidate is a water-soluble dimeric copper centred polyglycine coordination complex. It is administered through topical and transdermal route in the form of spray and gel.

RR MedSciences overview

RR MedSciences engaged in research and development of novel analgesics for the treatment of skeletal, neuropathic and inflammatory pain. The company is headquartered in Chatswood, New South Wales, Australia.

For a complete picture of RM-191A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.